1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Recurrent Head And Neck Cancer Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Recurrent Head And Neck Cancer Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Head And Neck Cancer Squamous Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Head And Neck Cancer Squamous Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Head And Neck Cancer Squamous Cell Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Recurrent Head And Neck Cancer Squamous Cell Carcinoma 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Recurrent Head And Neck Cancer Squamous Cell Carcinoma to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Recurrent Head And Neck Cancer Squamous Cell Carcinoma to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Recurrent Head And Neck Cancer Squamous Cell Carcinoma 26
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials 34
Prominent Drugs 36
Clinical Trial Profiles 37
Clinical Trial Overview of Top Companies 37
Sanofi 37
Clinical Trial Overview of Sanofi 37
E. Merck KG 38
Clinical Trial Overview of E. Merck KG 38
Novartis AG 40
Clinical Trial Overview of Novartis AG 40
Eli Lilly and Company 41
Clinical Trial Overview of Eli Lilly and Company 41
AstraZeneca PLC 42
Clinical Trial Overview of AstraZeneca PLC 42
F. Hoffmann-La Roche Ltd. 43
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 43
Pfizer Inc. 44
Clinical Trial Overview of Pfizer Inc. 44
Amgen Inc. 45
Clinical Trial Overview of Amgen Inc. 45
GlaxoSmithKline plc 46
Clinical Trial Overview of GlaxoSmithKline plc 46
C. H. Boehringer Sohn AG and Co. KG 47
Clinical Trial Overview of C. H. Boehringer Sohn AG and Co. KG 47
Clinical Trial Overview of Top Institutes / Government 48
National Cancer Institute 48
Clinical Trial Overview of National Cancer Institute 48
The University of Texas M. D. Anderson Cancer Center 53
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 53
European Organization for Research and Treatment of Cancer 54
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 54
The University of Chicago 55
Clinical Trial Overview of The University of Chicago 55
Memorial Sloan Kettering Cancer Center 56
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 56
University of Pittsburgh 57
Clinical Trial Overview of University of Pittsburgh 57
Southwest Oncology Group 58
Clinical Trial Overview of Southwest Oncology Group 58
Roswell Park Cancer Institute 59
Clinical Trial Overview of Roswell Park Cancer Institute 59
Sidney Kimmel Comprehensive Cancer Center 60
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 60
Eastern Cooperative Oncology Group 61
Clinical Trial Overview of Eastern Cooperative Oncology Group 61
Five Key Clinical Profiles 62
Appendix 173
Abbreviations 173
Definitions 173
Research Methodology 174
Secondary Research 174
About GlobalData 175
Contact Us 175
Disclaimer 175
Source 176

List of Tables
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2014* 8
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 15
Proportion of Recurrent Head And Neck Cancer Squamous Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Recurrent Head And Neck Cancer Squamous Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2014* 22
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 23
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Suspended Clinical Trials, 2014* 26
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 27
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 37
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 38
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 40
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 41
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 42
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 43
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 44
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 45
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 46
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG and Co. KG, 2014* 47
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 48
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 53
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 54
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 55
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 56
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 57
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 58
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014* 59
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014* 60
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 61

List of Figures
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 15
Proportion of Recurrent Head And Neck Cancer Squamous Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Recurrent Head And Neck Cancer Squamous Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 22
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 23
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36
GlobalData Methodology 174

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.